Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
NCT00609739Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jun 1999
- Primary completion
- Jun 2010
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in juvenile myelomonocytic leukemia (JMML), sponsored by Masonic Cancer Center. Started Jun 1999; status: terminated.
02
Drugs
cytarabinemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT00609739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00609739.